PD23-06 CHANGE IN SEXUAL FUNCTION IN MEN WITH LUTS/BPH ASSOCIATED WITH LONG-TERM TREATMENT WITH DOXAZOSIN, FINASTERIDE, AND COMBINED THERAPY

2014 ◽  
Vol 191 (4S) ◽  
Author(s):  
R. Charles Welliver ◽  
Chyng-Wen Fwu ◽  
Paul W. Eggers ◽  
Ziya Kirkali ◽  
Kevin T. McVary ◽  
...  
Keyword(s):  
Sexual Function ◽  
Combined Therapy ◽  
Term Treatment ◽  
Long Term Treatment

scholarly journals Hepatitis C virus-associated cryoglobulinemic vasculitis: A 20-year experience with treatment

2017 ◽  
Vol 89 (5) ◽  
pp. 46-52 ◽  
Author(s):  
T M Ignatova ◽  
L V Kozlovskaya ◽  
N B Gordovskaya ◽  
O A Chernova ◽  
S Yu Milovanova ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Combined Therapy ◽  
Multivariate Logistic Regression Analysis ◽  
Virologic Response ◽  
Term Treatment ◽  
Cryoglobulinemic Vasculitis ◽  
Multidisciplinary Therapy ◽  
Long Term Treatment

Aim. To summarize the experience of a multidisciplinary therapy hospital in treating patients with hepatitis C virus (HCV)-associated cryoglobulinemic vasculitis (CV). Subjects and methods. Seventy-two patients (mean age, 49.4±10.3 years) with HCV-associated CV were examined and followed up for an average period of 2.8±3.6 years. The efficiency of traditional (corticosteroids ± cyclophosphamide) and selective (rituximab) immunosuppressive therapy (IST) was estimated in 31 and 15 observations, respectively, and that of antiviral therapy (AVT) in 25. Vasculitis activity was assessed using the Birmingham vasculitis activity score (BVAS). The patients’ survival was studied; multivariate logistic regression analysis was carried out. Results. 24 (33.4%) of the 72 patients had a stage of liver cirrhosis (LC). The pretreatment mean BVAS was 11.9±7.2 (range 2 to 36). Severe CV (BVAS ≥15) was present in 30.6% of the patients. AVT was accompanied by achievement of sustained virologic response in 48% of the patients, clinical remission in 68% and had an advantage over IST in relation to long-term treatment results. Rituximab was significantly more effective than traditional immunosuppressants (remission rates of 73 and 13%, respectively). Combined therapy (rituximab and AVT) was most effective in patients with severe forms of vasculitis. Sixteen patients died from complications of vasculitis (37.5%), infection (37.5%), and LC (25%). The factors adversely affecting prognosis were age >55 years (odds ratio (OR), 4.49), the presence of LC (OR, 3.68), renal failure (OR, 4.66) and the use of glucocorticosteroids (OR, 3.91). Conclusion. HCV-associated CV can determine the prognosis of chronic HСV infection. AVT is the treatment of choice in all patients with HСV-associated CV. AVT must be combined with rituximab therapy in patients with severe forms of vasculitis.

scholarly journals Effects of long-term treatment with Dienogest on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain

2019 ◽  
Vol Volume 12 ◽  
pp. 2371-2378 ◽  
Author(s):  
Salvatore Caruso ◽  
Marco Iraci ◽  
Stefano Cianci ◽  
Salvatore Giovanni Vitale ◽  
Valentina Fava ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Sexual Function ◽  
Pelvic Pain ◽  
Term Treatment ◽  
Long Term Treatment

scholarly journals Androgen hormones and sexual function among cancer survivors: short and long-term treatment effects

2019 ◽  
Vol 112 (3) ◽  
pp. e103-e104
Author(s):  
Leigh A. Humphries ◽  
Katherine E. Cameron ◽  
Mary D. Sammel ◽  
Clarisa R. Gracia
Keyword(s):  
Sexual Function ◽  
Cancer Survivors ◽  
Treatment Effects ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Short And Long Term

Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension

Neurology ◽  
2017 ◽  
Vol 89 (10) ◽  
pp. 1078-1086 ◽  
Author(s):  
Jung-Ick Byun ◽  
Jangsup Moon ◽  
Do-Yong Kim ◽  
Hyerim Shin ◽  
Jun-Sang Sunwoo ◽  
...  
Keyword(s):  
Orthostatic Hypotension ◽  
Combined Therapy ◽  
Term Treatment ◽  
Open Label ◽  
Treatment Groups ◽  
Long Term Treatment ◽  
Secondary Endpoints ◽  
Orthostatic Symptoms

Objective:To evaluate the long-term (for up to 3 months) efficacy and safety of single or combined therapy with midodrine and pyridostigmine for neurogenic orthostatic hypotension (OH).Methods:This was a randomized, open-label clinical trial. In total, 87 patients with symptomatic neurogenic OH were enrolled and randomized to receive 1 of 3 treatments: midodrine only, pyridostigmine only, or midodrine + pyridostigmine. The patients were followed up at 1 and 3 months after treatment. The primary outcome measures were improvement in orthostatic blood pressure (BP) drop at 3 months. Secondary endpoints were improvement of the orthostatic BP drop at 1 month and amelioration of the questionnaire score evaluating OH-associated symptoms.Results:Orthostatic systolic and diastolic BP drops improved significantly at 3 months after treatment in all treatment groups. Orthostatic symptoms were significantly ameliorated during the 3-month treatment, and the symptom severity was as follows: midodrine only < midodrine + pyridostigmine < pyridostigmine only group. Mild to moderate adverse events were reported by 11.5% of the patients.Conclusions:Single or combination treatment with midodrine and pyridostigmine was effective and safe in patients with OH for up to 3 months. Midodrine was better than pyridostigmine at improving OH-related symptoms.Clinicaltrials.gov identifier:NCT02308124.Classification of evidence:This study provides Class IV evidence that for patients with neurogenic OH, long-term treatment with midodrine alone, pyridostigmine alone, or both midodrine and pyridostigmine is safe and has similar effects in improving orthostatic BP drop up to 3 months.

Long-Term Treatment of Essential Hypertension with Nadolol and Hydrochlorothiazide: A Two-Year Follow-Up

1982 ◽  
Vol 10 (2) ◽  
pp. 87-91 ◽  
Author(s):  
M M El-Mehairy ◽  
A Shaker ◽  
M Ramadan ◽  
S Hamza ◽  
S S Tadros
Keyword(s):  
Blood Pressure ◽  
Essential Hypertension ◽  
Combined Therapy ◽  
Term Treatment ◽  
Once Daily ◽  
Supine Blood Pressure ◽  
End Of Treatment ◽  
Long Term Treatment ◽  
Adrenergic Blocker

After 3 weeks of placebo administration, thirty-two mildly or moderately hypertensive patients were treated with hydrochlorothiazide (HCZ) for 3 weeks, then with HCZ plus nadolol, a new beta-adrenergic blocker, for 2 years. The dose of HCZ was 50 mg once daily for all except two patients, who received 50 mg twice a day. The dose of nadolol ranged from 40 mg to 240 mg, once daily. The average supine blood pressure decreased from 182/110 mm Hg at the end of the placebo period to 170/104 mm Hg at the end of treatment with HCZ alone. Nadolol was added to the regimen, and the average supine blood pressure decreased further to 132/88 mm Hg at the end of 3 months of combined therapy. It remained essentially unchanged for the duration of the 2-year study, and no increases in the dosage of either drug were needed. Side-effects were mild, and none required a change in dosage. A once-daily dose of nadolol combined with HCZ appears to be safe and effective therapy for the long-term treatment of mild or moderate essential hypertension.

Effects of long-term treatment with the GnrH agonist deslorelin (Suprelorin®) on sexual function in boars

2010 ◽  
Vol 74 (5) ◽  
pp. 733-740 ◽  
Author(s):  
Johannes Kauffold ◽  
Hartmut Rohrmann ◽  
Julia Boehm ◽  
Axel Wehrend
Keyword(s):  
Sexual Function ◽  
Gnrh Agonist ◽  
Term Treatment ◽  
Long Term Treatment

scholarly journals Long-term treatment of canine cyclic hematopoiesis with recombinant canine stem cell factor

Blood ◽  
1995 ◽  
Vol 85 (1) ◽  
pp. 74-79 ◽  
Author(s):  
DC Dale ◽  
E Rodger ◽  
J Cebon ◽  
N Ramesh ◽  
WP Hammond ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Factor ◽  
Combined Therapy ◽  
Term Treatment ◽  
Response Curves ◽  
Hematopoietic Stem ◽  
Cell Counts ◽  
Long Term Treatment ◽  
Cyclic Hematopoiesis

Grey collie dogs have cyclic fluctuations in their blood cell counts caused by a regulatory defect of hematopoietic stem cells. To examine the role of stem cell factor (SCF) or its receptor in this disorder, we investigated the stimulatory effects of recombinant canine SCF (rc-SCF) on in vitro marrow cultures, cloned and sequenced the grey collie SCF gene, and treated three grey collies with rc-SCF, either alone or in combination with recombinant canine granulocyte colony-stimulating factor (rcG-CSF). Colony-forming unit granulocyte-macrophage formation from grey collie or normal dog marrow showed similar dose-response curves for rc-SCF. Cloning and sequencing the SCF gene for two grey collies showed no evidence of mutations in the coding region of the SCF gene. Treatment with rc-SCF (10 to 100 micrograms/kg/d) did not induce neutrophilia except at the highest dose (100 micrograms/kg/d), but daily rc-SCF abrogated the neutropenic periods in doses of 20 micrograms/kg/d or greater. Combination of rc-G-CSF (0.5 to 1.0 microgram/kg/d) with rc-SCF treatment (20 to 50 micrograms/kg/d) suggested a synergistic effect, ie, the neutrophil levels on combined therapy were higher than the sum of the levels when these two cytokines were given separately. Long-term treatment of these dogs with rc-SCF in doses of 10 to 30 micrograms/kg/d was generally well tolerated, suggesting that SCF may be useful as a therapy for some chronic hypoproliferative disorders of hematopoiesis.

scholarly journals Effect of long-term treatment with fenspiride (Erespal) on clinical and functional status of patients with chronic obstructive lung disease

2005 ◽  
pp. 92-94
Author(s):  
A. A. Visel ◽  
E. Yu. Pronina ◽  
I. Yu. Visel ◽  
M. A. Yunusova
Keyword(s):  
Combined Therapy ◽  
Randomized Study ◽  
Combined Treatment ◽  
Chronic Obstructive Lung Disease ◽  
Term Treatment ◽  
Chronic Obstructive ◽  
Copd Patients ◽  
Long Term Treatment ◽  
Clinical And Functional Status

This open comparative randomized study has shown that fenspiride is an effective and well-tolerated drug while being administered in combined therapy of COPD for 3 to 12 months. The anti-inflammatory action of fenspiride 80 mg t. i. d. significantly reduced cough in COPD patients and enhanced the effect of bronchodilators. Fenspiride (Erespal) can be included in standards of combined treatment of patients with mild, moderate and severe COPD.

Sign in / Sign up

Export Citation Format

Share Document